文献速递静脉血栓栓塞慢性静脉疾病

非恶性下腔静脉梗阻腔内重建的中期结果

Medium-term outcomes after inferior vena cava reconstruction for acute and chronic deep vein thrombosis and retroperitoneal fibrosis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-09-08

本研究回顾性分析59例因非恶性下腔静脉梗阻接受腔内重建患者的资料,按膝下流入道血管质量分三组。中位随访2年3个月,全队列1、3、5年一期通畅率分别为91.2%、71.0%、24.1%,流入道组A通畅率显著优于B和C组,血栓后综合征患者Villalta评分和生活质量改善。

要点

  • 腔内重建对非恶性下腔静脉梗阻可获得良好通畅率和临床症状改善。
  • 股静脉/股深静脉血栓后病变患者的中期通畅率较差。
  • 流入道血管质量是影响通畅率的重要因素。

核心结论

  • 非恶性下腔静脉梗阻腔内重建可获得良好通畅率和临床改善,但股静脉和股深静脉血栓后病变患者结果较差。

研究设计与样本

  • 回顾性分析2014年2月至2019年1月连续59例因非恶性梗阻接受腔内下腔静脉重建患者的术前、术中、随访病历和影像资料。
  • 按膝下流入道血管质量分为三组:A组无股静脉或股深静脉血栓后病变;B组一或两条膝下流入道静脉狭窄;C组三条膝下流入道静脉均狭窄或股静脉和/或股深静脉闭塞。

主要发现

  • 治疗指征为血栓后综合征41例、急性深静脉血栓12例、腹膜后纤维化6例。
  • 中位年龄37岁11个月,男性占71.2%,32.2%诊断易栓症,三组人口学无显著差异。
  • 中位随访2年3个月(范围6个月至6年5个月)。
  • 全队列1、3、5年一期通畅率分别为91.2%、71.0%、24.1%;二期通畅率1年76.7%,3年和5年均为66.4%。

关键数值与推荐

  • 血栓后综合征患者Villalta评分从基线均值14.2降至1年8.1、2年6.8。
  • 血栓后综合征患者静脉功能不全流行病学和经济研究生活质量评分从基线均值19.8改善至1年54.1、2年57.3。
  • 急性深静脉血栓患者Villalta评分1年2.8、2年0。
  • 腹膜后纤维化患者生活质量评分从基线均值25.3改善至6个月44。

临床怎么用

  • 腔内重建可用于非恶性下腔静脉梗阻,但需评估膝下流入道血管质量以预测通畅率。
  • 股静脉和股深静脉血栓后病变患者中期通畅率较差,应加强随访和再干预准备。

局限性

  • 回顾性研究,样本量59例,随访时间有限。
  • 单中心经验,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the present study, we evaluated the technical and clinical outcomes after endovascular inferior vena cava (IVC) reconstruction in patients with nonmalignant obstruction. METHODS: The preoperative, procedural, and follow-up medical records and imaging studies were retrospectively reviewed for 59 consecutive patients who had undergone endovascular IVC reconstruction for nonmalignant obstruction from February 2014 to January 2019. The patients were classified into three groups according to the quality of their infrainguinal inflow vessels. The outcomes measured were the primary, primary-assisted, and secondary patency rates, reintervention rates, and symptomatic resolution. RESULTS: The indications for treatment were post-thrombotic syndrome (n = 41), acute deep vein thrombosis (n = 12), and retroperitoneal fibrosis (n = 6). The median patient age was 37 years, 11 months, 71.2% were men, and 32.2% had a diagnosis of thrombophilia, with no significant difference in these demographics between the three inflow groups. The median follow-up duration was 2 years, 3 months (range, 6 months to 6 years, 5 months). The whole-cohort primary patency was 91.2%, 71.0%, and 24.1% at 1, 3, and 5 years, respectively. Secondary patency was 76.7% at 1 year and 66.4% at both 3 and 5 years. Inflow group A (no post-thrombotic disease in the femoral or deep femoral veins) demonstrated significantly higher primary patency compared with group B (stenotic disease in one or two infrainguinal inflow veins; P = .009) and significantly higher secondary patency than for both groups B (P = .008) and C (all three infrainguinal inflow veins had stenosed or femoral and/or deep femoral vein occlusion was present; P = .04). In post-thrombotic syndrome patients, the Villalta scores had decreased from a mean of 14.2 to 8.1 at 1 year and 6.8 at 2 years, and the Venous Insufficiency Epidemiological and Economic Study Quality of Life score had improved from a mean of 19.8 to 54.1 and 57.3 at 1 and 2 years, respectively. In the patients with acute deep vein thrombosis, the Villalta score was 2.8 at 1 year and 0 at 2 years. In the patients with retroperitoneal fibrosis, the Venous Insufficiency Epidemiological and Economic Study Quality of Life score had improved from a mean of 25.3 at baseline to 44 at 6 months. CONCLUSIONS: Endovascular IVC reconstruction for nonmalignant obstruction can achieve good patency and clinical improvement, although the outcomes were poorer for patients with post-thrombotic disease of the femoral and deep femoral veins.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Thulasidasan N, Morris R, Theodoulou I, et al. Medium-term outcomes after inferior vena cava reconstruction for acute and chronic deep vein thrombosis and retroperitoneal fibrosis. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34508871. doi:10.1016/j.jvsv.2021.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。